
WILEY

An Overview of Psoriasis and Atopic Dermatitis

Clinical presentation, differential diagnosis, and management of disease


Prevalence, overlapping features, and pathogenesis of psoriasis (PSO) and atopic dermatitis (AD)¹



Asian patients with PSO are susceptible to metabolic and neurologic comorbidities and need to be monitored appropriately¹⁰

> Visit https://dermatology.apac.knowledgehub.wiley.com for additional resources

PSO - clinical presentation, differential diagnosis, diagnostic criteria, and complications



Visit https://dermatology.apac.knowledgehub.wiley.com for additional resources


Clinical presentation, differential diagnosis, and management of AD



Characterised by the presence of eczema, intense pruritus, and dry skin




Eczema and pruritis are a result of altered barrier function of the skin and dysfunction of the immune system



Visit <u>https://dermatology.apac.knowledgehub.wiley.com</u> for additional resources

Dermatology is vital to enhancing the treatment outcomes

Treatment approaches, therapeutic drugs, and biologics for PSO and AD



References:

Published by

IIFY

Tsai, Y. C., & Tsai, T. F. (2022). Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes. International Journal of Molecular Sciences, 23(10), 5518. Chen, W. Y., Chen, S. C., Hsu, S. Y., Lin, Y. A., Shih, C. M., Huang, C. Y., ... & Lee, A. W. (2022). Annoying psoriasis and atopic dermatitis: a narrative review. International Journal of Molecular Sciences, 23(9), 4898.

Key takeaways

🐼 With increased patient adherence, currently available therapies can enhance the overall QoL

🐼 Timely and accurate diagnosis of PSO and AD is vital for improving patient outcomes

Rendon, A., & Schäkel, K. (2019). Psoriasis pathogenesis and treatment. International Journal of Molecular Sciences, 20(6), 1475.

IL-23 inhibitors

IL-12/23 inhibitors

- 6. 7.
- Kendon, A., & Schakel, K. (2019). Psoriasis pathogenesis and treatment. *International Journal of Molecular Sciences*, 20(6), 1475.
 Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021). Psoriasis. *The Lancet*, 397(10281), 1301–1315.
 Ständer S. (2021). Atopic dermatitis. *The New England Journal of Medicine*, 384(12), 1136–1143.
 Langan, S. M., Irvine, A. D., & Weidinger, S. (2020). Atopic dermatitis. *The Lancet*, 396(10247), 345–360.
 Chang, Y. C., Wu, W. M., Chen, C. H., Hu, C. F., & Hsu, L. A. (2008). Association between P478S polymorphism of the *filaggrin* gene and risk of psoriasis in a Chinese population in Taiwan. *Archives of Dermatical December*, 20(2).

Chang, Y. C., Wu, W. M., Chen, C. H., Hu, C. F., & Hsu, L. A. (2008). Association between P4785 polymorphism of the *Juggrin* gene and risk of psoriasis in a Chinese population. In Taiwan: Archives of *Dermatological Research*, 300(3), 133–137. Hu, Z., Xiong, Z., Xu, X., Li, F., Lu, L., Li, W., ... & Xia, K. (2012). Loss-of-function mutations in *filaggrin* gene associate with psoriasis vulgaris in Chinese population. *Human Genetics*, 131, 1269–1274. Baurecht, H., Hotze, M., Brand, S., Büning, C., Cormican, P., Corvin, A., ... & Brown, S. J. (2015). Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms. *The American Journal of Human Genetics*, 96(1), 104–120. Yang, H. J., Lee, M. Y., Lee, J. H., Jung, C. J., Lee, W. J., Won, C. H., ... & Chang, S. E. (2024). Comparison of metabolic and neurological comorbidities in Asian patients with psoriasis and atopic dermatitis. *Scientific Reports*, 14(1), 4212. Armstrong, A. W., & Read, C. (2020). Pathophysiology, clinical presentation, and treatment of psoriasis: a review. *JAMA*, 323(19), 1945–1960. Armario Hita, J. C., Galán-Gutiérrez, M., Dodero-Anillo, J. M., Carrascosa, J. M., & Ruiz-Villaverde, R. (2023). Updated review on treatment of atopic dermatitis. *Journal of Investigational Allergology & Clinical Psoriasis*, 210, 128–167.

- 10.
- 12.
- 13.
- Armario Hita, J. C., Galàn-Guttérrez, M., Dodero-Anillo, J. M., Carrascosa, J. M., & Ruiz-Villaverde, R. (2023). Updated review on treatment of atopic dermatitis. *Journal of Investigational Allergology & Clinical Immunology*, *33*(3), 158–167. Frazier, W., & Bhardwaj, N. (2020). Atopic dermatitis: diagnosis and treatment. *American Family Physician*, *101*(10), 590–598. Stern, R. S., & Nelson, C. (1993). The diminishing role of the dermatologist in the office-based care of cutaneous diseases. *Journal of the American Academy of Dermatology*, *29*(5 Pt 1), 773–777. Eichenfield, L. F., Tom, W. L., Chamlin, S. L., Feldman, S. R., Hanifin, J. M., Simpson, E. L., ... & Sidbury, R. (2014). Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. *Journal of the American Academy of Dermatology*, *70*(2), 338–351. Ersser, S. J., Cowdell, F., Latter, S., Gardiner, E., Flohr, C., Thompson, A. R., ... & Drury, A. (2014). Psychological and educational interventions for atopic eczema in children. *Cochrane Database of Systematic Reviews*, (1), CD004054. 14 15.
- 16.
- 17.
- Systemula Reviews, (1), Educadosa, Hon, K. L., Kung, J. S. C., Ng, W. G. G., & Leung, T. F. (2018). Emollient treatment of atopic dermatitis: latest evidence and clinical considerations. *Drugs in Context*, 7, 212530.
 Van Zuuren, E. J., Fedorowicz, Z., Christensen, R., Lavrijsen, A., & Arents, B. W. M. (2017). Emollients and moisturisers for eczema. *Cochrane Database of Systematic Reviews*, 2(2), CD012119.
 Eichenfield, L. F., Torn, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., ... & Sidbury, R. (2014). Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. *Journal of the American Academy of Dermatology*, 7(1), 116–132.
 Schneider, L., Tilles, S., Lio, P., Boguniewicz, M., Beck, L., LeBovidge, J., ... & Wallace, D. (2013). Atopic dermatitis: a practice parameter update 2012. *Journal of Allergy and Clinical Immunology*, 131(2), 2017. 18 19.
- 20. 295-299.





Tralokinumab and lebrikizumab are IL-13 inhibitors